ATHIRA PHARMA INC (ATHA) Stock Income Statement
NASDAQ:ATHA - Nasdaq - US04746L1044 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 96.78M | 127.09M | 94.02M | 64.02M | 20.00M | |||
| Research and Development | 70.68M | 93.79M | 61.46M | 42.79M | 13.29M | |||
| Selling, General, and Administrative Expenses | 26.09M | 33.30M | 32.55M | 21.23M | 6.71M | |||
| Operating Income | -96.78M | -127.09M | -94.02M | -64.02M | -20.00M | |||
| Interest Income/Expense | N/A | N/A | N/A | 330.00K | -1.02M | |||
| Other Income/Expense | 3.96M | 7.79M | 8.38M | 8.84M | 860.00K | |||
| Non Recurring Items | -4.13M | 1.63M | -10.00M | 0.00 | 200.00K | |||
| Income Before Taxes | -96.94M | -117.67M | -95.64M | -54.85M | -19.96M | |||
| Net Income | -96.94M | -117.67M | -95.64M | -54.85M | -19.96M | |||
| EBITDA | -95.81M | -126.13M | -93.17M | -63.54M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.52 | -3.10 | -2.53 | -1.49 | -0.61 | |||
| Non GAAP EPS | -2.53 | -3.09 | -2.27 | -1.50 | N/A | |||
| Statistics | ||||||||
All data in USD